Wyeth is now

Company snapshot

Wyeth is now is a pharma organization headquartered in CN. Primary therapeutic focus areas include Graft Rejection, Arrhythmias, Depressive Disorder, Major, Rheumatoid Arthritis, Hemophilia A. NovaPharmaNews links 9 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: approved (5), phase 3 (2), phase 2 (1).

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Wyeth is now. Not investment advice.

• Peer + 0 momentum

  Sanofi Pasteur MSD

  TA overlap score 36.6

Recent activity

Latest pipeline, patent, and corporate events for Wyeth is now.

1. Jun 8, 2026 Clinical update

   Etanercept , Methotrexate — Approved

2. Jun 8, 2026 Clinical update

   cyclosporine or tacrolimus — Approved

3. Jun 5, 2026 Clinical update

   SAM-315 — Phase 1

4. May 26, 2026 Clinical update

   DVS SR — Phase 3

5. May 26, 2026 Clinical update

   tigecycline — Phase 3

View all clinical trial activity →

• What is Wyeth is now?

  Wyeth is now is a pharma organization headquartered in CN. Primary therapeutic focus areas include Graft Rejection, Arrhythmias, Depressive Disorder, Major, Rheumatoid Arthritis, Hemophilia A. NovaPharmaNews links 9 clinical program(s), 0 drug profile(s), and 0 patent record(s) t

• Is Wyeth is now publicly traded?

  Wyeth is now appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Wyeth is now develop or market?

  We link 8 drug profile(s) where Wyeth is now is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/pfizer-ireland-pharmaceuticals#company-drugs.

• What are the latest developments for Wyeth is now?

  In the last 12 months our linked public records show 9 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Wyeth is now focus on?

  Wyeth is now focuses on Graft Rejection, Arrhythmias, Depressive Disorder, Major based on our analysis of their pipeline programs and drug development activities.